Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE])

American Journal of Cardiology

Volumn 91, Issue 6, 2003, Pages 667-672

  Bays, Harold E ^a   Dujovne, Carlos A ^b   McGovern, Mark E ^b   White, T Eric ^b   Kashyap, Moti L ^b   Hutcheson, A Gene ^b   Crouse, John R ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0037443567     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00007-9     Document Type: Article

References (18)

1. Bazalo G.R. Managed care trends in statin usage. Manag Care. 10:2001;48-59.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
3. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin. J Am Coll Cardiol. 8:1986;1245-1255.
4. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
6. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
7. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
9. Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol. 90:2002;30k-43k.
10. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2:2000;36-46.
11. Blumenthal R.S. Statins effective antiatherosclerotic therapy. Am Heart J. 139:2000;577-583.
12. Stein E.A., Davidson M.H., Dujovne C.A., Hunninghake D.B., Goldberg R.B., Illingworth D.R., Knopp R.H., Miller V.T., Frost P., Isaacsohn J.L., et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia a prospective trial. J Cardiovasc Pharmacol Ther. 1:1996;107-116.
13. Tsalamandris C., Panagiotopoulos S., Sinha A., Cooper M.E., Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1:1994;231-239.
14. Vacek J.L., Dittmeier G., Chiarelli T., White J., Bell H.H. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 76:1995;182-184.
15. Brown B.G., Zhao X.-Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
16. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 32:1991;383-394.
17. Griffin B.A., Skinner E.R., Maughan R.J. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis. 70:1988;165-169.
18. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., Brody J. Efficacy and safety of an extended-release niacin (Niaspan) a long-term study. Am J Cardiol. 82:1998;74U-81U.